Cognition Therapeutics: oral zervimesine cuts GA lesion growth 28.6% in Phase 2 trial

COGNITION THERAPEUTICS INC

Zervimesine-treated patients had 28.6% slower GA lesion growth rate vs placebo in Phase 2 MAGNIFY study.
At 18 months, mean lesion size was 28.2% smaller for zervimesine group compared to placebo.
Trial concluded early with ~100 of planned 246 enrolled; company focuses resources on Alzheimer's and DLB programs.
Dry AMD is third indication where zervimesine showed efficacy signals; oral pill vs current injectable treatments.
Additional safety, demographic, and visual outcome data still being analyzed; results to be presented at medical meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.